Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00408434 · ClinicalTrials.gov registry record · Phase 1

Study of an Experimental New Drug, PPARγ Agonist Taken by Mouth by Participants With Advanced or Metastatic Cancer

A Phase 1 study of Neoplasm, sponsored by Daiichi Sankyo.

Completed
Registry status
Phase 1
Development phase
32
Enrollment target
2
Study locations

NCT00408434 is a Phase 1 study of Neoplasm that has completed, run by Daiichi Sankyo. The registered enrollment target is 32 participants, below the 199-participant average among 11 other Neoplasm trials with a reported enrollment target (84% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00408434, a Phase 1 study of Neoplasm, has completed, sponsored by Daiichi Sankyo.

COMPLETED
Registry status
Phase 1
Development phase
32 participants
Enrollment target
2
Study locations

Study Summary

An open-label, Phase I, dose escalation study of CS-7017 administered by mouth in sequential cohorts of 3 to 6 participants with advanced or metastatic malignancies.

Conditions Studied

Neoplasm

Interventions

  • DRUG CS-7017

Study Locations (2)

District of Columbia

  • - Washington D.C.

Massachusetts

  • - Boston

Trial Details

FieldValue
Enrollment Target 32 participants
Start Date 2006-11
Est. Completion 2010-02
Phase Phase 1

Sponsor

Daiichi Sankyo

236 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00408434

The ClinicalTrials.gov registry entry for NCT00408434 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 199-participant average among 11 other Neoplasm trials with a reported enrollment target (84% lower). The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Neoplasm appearing as the primary indexed condition, and to 1 intervention - of which CS-7017 is the first listed.

NCT00408434 reports 2 study locations spanning 2 distinct geographic areas - top geographies include District of Columbia, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT00408434 about?

NCT00408434 is a clinical study titled "Study of an Experimental New Drug, PPARγ Agonist Taken by Mouth by Participants With Advanced or Metastatic Cancer". An open-label, Phase I, dose escalation study of CS-7017 administered by mouth in sequential cohorts of 3 to 6 participants with advanced or metastatic malignancies.

What is the current status of trial NCT00408434?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2006-11. Estimated completion is 2010-02.

What conditions does trial NCT00408434 study?

This clinical trial studies the following conditions: Neoplasm.

What interventions are being tested in trial NCT00408434?

The interventions under investigation include: CS-7017 (DRUG).

Who is sponsoring clinical trial NCT00408434?

This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00408434 being conducted?

This trial has 2 study locations across District of Columbia, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Neoplasm

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Neoplasm

All registered trials for this condition

District of Columbia

All trials with a study site in District of Columbia

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.